Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ...
Clinical Trials Arena

Sanofi’s bispecific scores in respiratory diseases but fails in eczema

Credit: Below the Sky / Shutterstock.com Two of Sanofi’s lunsekimig Phase II trials have met their primary endpoints in respiratory disease, while a study in atopic dermatitis failed to show benefit.
pulmonologyadvisor

IL-33 Inhibitor Tozorakimab Reduces COPD Exacerbations in Phase 3 Trials

Clinical benefits of the interleukin-33 inhibitor were observed in a broad population, including both former and current smokers, regardless of eosinophil levels. Topline results were announced from ...

AstraZeneca Shares Surge on COPD Trial Success

AstraZeneca shares were up about 3.5% Friday after the company said its drug for COPD, a deadly lung disease often caused by smoking, slowed patients' symptoms in two large trials. The drug, ...
BioPharma Dive

AstraZeneca lung drug gets ‘surprise’ win in COPD trials

AstraZeneca didn’t release complete data from the trials, called Oberon and Titania, stating that they will be disclosed at an upcoming medical meeting. Those details will be closely watched.
Nature

Extreme climate outcomes could still occur with just 2 °C of global warming

Rachel Warren is at the Tyndall Centre for Climate Change Research, University of East An-glia, Norwich NR4 7TJ, UK. The Paris agreement, an international treaty on climate change, aims to limit the ...
American College of Cardiology

The Health Impacts of Alcohol Depend on What You Drink – And How Much

While high alcohol intake has been associated with worse health outcomes regardless of the type of alcohol consumed, the potential impacts of low to moderate alcohol intake appear to vary by beverage ...